Run for skin and hair
GLOW 42
Fixed-ratio blendintermediate4 weeksA fixed three-peptide repair and skin blend sold in a single 42 mg vial: GHK-Cu, BPC-157 and TB-500. This is the original GLOW blend, and it is exactly KLOW with the KPV left out - KLOW is GLOW plus KPV, which is where the leading K in KLOW comes from. Run as one daily subcutaneous shot for skin, soft tissue and connective tissue work.
Also sold as GLOW, GLOW Blend, GHK-Cu + BPC-157 + TB-500, KLOW without KPV.
What the ratio costs you
3 of these 3 compounds come out of one vial.
You cannot dose them independently. Every draw moves all 3 together in a ratio fixed by whoever filled the vial, so the only way to raise the component you care about is to raise the others with it.
- The ratio is fixed in the vial. Titrating one component means titrating all three, so if the copper load is too high for you the whole stack has to come down.
- The TB-500 dose this blend delivers is far below a standalone TB-500 protocol - roughly a tenth of a loading dose. If you are buying GLOW for TB-500, you are mostly buying GHK-Cu.
- Blends cannot be split. If you react badly you will not know which of the three caused it, which is the main argument for running the components separately first.
Cautions — 8 on record
Read before running any of this
- GHK-Cu delivers copper. Chronic high-dose use alongside a copper-containing multivitamin can push copper up and zinc down; run defined blocks (commonly 4 weeks on, 2-4 weeks off) rather than dosing continuously.
- Not for use in pregnancy.
- Do not run it with an active malignancy. GHK-Cu, BPC-157 and TB-500 are all pro-angiogenic or pro-proliferative in animal models.
- BPC-157, TB-500 and GHK-Cu are all unapproved for injection in humans. Every GLOW vial is research-chemical grade with no pharmacy oversight of purity or content.
- BPC-157 and TB-500 are banned by WADA. Do not run this if you are drug tested in sport.
The 3 fixed-ratio cautions are printed above, at the top of the page.
Components
What is in it, and when
| Compound | Dose | Frequency | Time | Notes | |
|---|---|---|---|---|---|
| GHK-CuRatio-locked | 1 mg1 mg–2 mg | Once daily7×/week | Evening | The bulk of the blend. A 42 mg GLOW vial is 30 mg GHK-Cu / 6 mg BPC-157 / 6 mg TB-500, so GHK-Cu is about 71% of every draw and cannot be dosed independently. Reconstituted with 2 mL of bacteriostatic water the vial is 21 mg/mL total blend, and a 7-unit (0.07 mL) draw delivers roughly 1050 mcg GHK-Cu with 210 mcg of each of the other two. GHK-Cu stings and can leave a temporary blue-green mark at the injection site. | Calculator → |
| BPC-157Ratio-locked | 200 mcg200 mcg–500 mcg | Once daily7×/week | Evening | Fixed at one fifth of the GHK-Cu dose by the 5:1:1 blend ratio. This lands at the bottom of the 200-500 mcg range people run BPC-157 at on its own, and you can only raise it by raising the copper with it. | Calculator → |
| TB-500Ratio-locked | 200 mcg200 mcg–500 mcg | Once daily7×/week | Evening | Also one fifth of the GHK-Cu dose. This is roughly a tenth of the 2-2.5 mg twice-weekly loading dose used when TB-500 is run on its own, and the ratio makes a real TB-500 load impossible without grossly overdosing the GHK-Cu. Add a separate TB-500 vial if loading is the point of the cycle. Exactly the same problem exists in KLOW. | Calculator → |
Doses are per administration, in the canonical unit. The second line under each dose is the range people run. For ratio-locked components the calculator link opens that compound on its own — a blend vial is one draw, so reconstitute against the vial total, not the component.
Delivered dose vs standalone dose
Where each component actually lands
Each bar is that compound’s own dose range from its monograph, with a marker where this protocol puts it. A marker outside the band means the protocol is not dosing that compound the way it is dosed on its own — for a fixed-ratio vial that is arithmetic, not a choice.
GHK-Cu
Ratio-lockedAt the floor of the range- Per dose
- 67% of typical
- Per week
- 7 mg · 67% of standalone
- Cycle total
- 28 mg · 28 doses
The bulk of the blend. A 42 mg GLOW vial is 30 mg GHK-Cu / 6 mg BPC-157 / 6 mg TB-500, so GHK-Cu is about 71% of every draw and cannot be dosed independently. Reconstituted with 2 mL of bacteriostatic water the vial is 21 mg/mL total blend, and a 7-unit (0.07 mL) draw delivers roughly 1050 mcg GHK-Cu with 210 mcg of each of the other two. GHK-Cu stings and can leave a temporary blue-green mark at the injection site.
BPC-157
Ratio-lockedAt the floor of the range- Per dose
- 80% of typical
- Per week
- 1.4 mg · 80% of standalone
- Cycle total
- 5.6 mg · 28 doses
Fixed at one fifth of the GHK-Cu dose by the 5:1:1 blend ratio. This lands at the bottom of the 200-500 mcg range people run BPC-157 at on its own, and you can only raise it by raising the copper with it.
TB-500
Ratio-lockedAt the floor of the range- Per dose
- 67% of typical
- Per week
- 1.4 mg · 67% of standalone
- Cycle total
- 5.6 mg · 28 doses
Also one fifth of the GHK-Cu dose. This is roughly a tenth of the 2-2.5 mg twice-weekly loading dose used when TB-500 is run on its own, and the ratio makes a real TB-500 load impossible without grossly overdosing the GHK-Cu. Add a separate TB-500 vial if loading is the point of the cycle. Exactly the same problem exists in KLOW.
Schedule — 4 weeks
Week by week
| Compound | 1Week 1 | 2Week 2 | 3Week 3 | 4Week 4 | Cycle total |
|---|---|---|---|---|---|
| GHK-Cu1 mg · 7×/wk | 28 mg28 doses | ||||
| BPC-157200 mcg · 7×/wk | 5.6 mg28 doses | ||||
| TB-500200 mcg · 7×/wk | 5.6 mg28 doses |
The dataset records one dose per component, so every dosing week is identical. Where a protocol note describes a loading phase followed by maintenance, that phase change is in the note, not in the schedule — read the component notes before assuming the grid is the whole story.
Evidence
What is actually known
RELATIONSHIP TO KLOW: GLOW = GHK-Cu + BPC-157 + TB-500. KLOW = GLOW + KPV. They are the same base blend and the same fixed-ratio problem; KLOW just adds an alpha-MSH fragment for the anti-inflammatory and gut arm. If you are choosing between them, the question is only whether you want KPV in the mix, because everything else about the two vials behaves the same. RATIO - PARTIALLY VERIFIED. The 5:1:1 GHK-Cu : BPC-157 : TB-500 ratio is what vendors and dosing guides consistently report for GLOW, and the 42 mg vial breaks down as 30 mg / 6 mg / 6 mg on that ratio, which is what the dosing guides that list a 42 mg size state. What is NOT standardised is the vial size: 70 mg (50/10/10) is the more commonly stocked size, and 90 mg vials at 70 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 are also sold, which is a 7:1:1 ratio rather than 5:1:1. Read the label and the certificate of analysis on the vial you actually bought before using the numbers here; do not assume your vial matches. EVIDENCE: there is no clinical trial of the blend as a blend. The evidence base is animal work on the individual components plus small human cosmetic studies of TOPICAL GHK-Cu at roughly 0.05-2%, which say nothing about injecting it systemically. Doses come from community and vendor protocols, not from a label.
SourcesPubMedClinicalTrials.gov
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.